Maraviroc/Etravirine Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Etravirine may speed up how quickly your liver processes maraviroc. However, other medicines may also affect maraviroc and they may cancel this effect.
What might happen:
The amount of maraviroc in your blood may increase or decrease, depending on what other medicines you are also taking.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you stop taking any of your medicines. Your doctor may want to change the dose of your medicine or check your blood to see how your medicine is working. Stop taking maraviroc and call your doctor right away if you develop yellow eyes or skin, dark urine, vomiting, or abdominal pain. Let your doctor know right away if you develop nausea, fever, flu-like symptoms, or fatigue, but continue taking your maraviroc. Let your doctor know if you have any kidney problems, which may make the interaction more severe.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Intelence (etravirine) UK summary of product characteristics. Janssen-Cilag Ltd August 28, 2008.
- 2.Spillane R. Personal communication. Pfizer U.S. Medical Information May 23, 2008.
- 3.Selzentry (maraviroc) US prescribing information. Pfizer Inc. October, 2020.
- 4.Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Presented at the 11th European AIDS Conference. Madrid, Spain. October 24-27, 2007.
- 5.Intelence (etravirine) US prescribing information. Janssen Pharmaceuticals August, 2014.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.